natgillin/translations-raw huggingface dataset:
Life-threatening or even fatal cutaneous reactions Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported with the use of teicoplanin. 
Med uporabo teikoplanina so bile opisane življenje ogrožujoče ali celo smrtne kožne reakcije, npr. Stevens-Johnsonov sindrom (SJS) in toksična epidermalna nekroliza (TEN).
400 mg intravenous or intramuscular (this equates to approximately 6 mg/kg body weight) every 12 hours for 3 administrations 
400 mg intravensko ali intramuskular no (to ustreza približno 6 mg/kg telesne mase) na 12 ur za 3 aplikacije
800 mg intravenous (this equates to approximately 12 mg/kg body weight) every 12 hours for 3 to 5 administrations 
800 mg intravensko (to ustreza približno 12 mg/kg telesne mase) na 12 ur za 3 do 5 aplikacij
Fluorescence Polarization Immunoassay (FPIA) method. 
Polarization Immunoassay).
Inherently resistant bacteria All Gram-negative bacteria Other bacteria 
Inherentno odporne bakterije Vse gramnegativne bakterije Druge bakterije Chlamydia spp.
Water for injections [See Annex I - To be completed nationally] 
Vehikel voda za injekcije [Glejte Prilogo I - Izpolni država članica]
Common (may affect up to 1 in 10 people) 
Pogosti (pojavijo se lahko pri največ 1 od 10 oseb)
IE IE 
/l.
This SmPC, labelling and packages leaflet is the version valid at the time of Commission decision. 
Ta verzija Povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo je veljavna ob izdaji Sklepa komisije.
After a maintenance dose of 12 mg/kg once daily Ctrough values range from 18 to 30 mg/L. 
Po vzdrževalnem odmerku 12 mg/kg enkrat na dan so vrednosti Cnajnižja od 18 do 30 mg
The solvent is packaged in Type I, colourless glass ampoule. 
Vehikel je pakiran v ampulo iz brezbarvnega stekla tipa I.
Infection caused by ‘Clostridium difficile' bacteria The recommended dose is 100 to 200 mg by mouth, twice a day for 7 to 14 days. 
Okužba, ki jo povzroča bakterija Clostridium difficile Priporočeni odmerek je od 100 do 200 mg peroralno (zaužitje) dvakrat na dan v trajanju od 7 do 14 dni.
• For endocarditis and other severe infections, teicoplanin trough levels of 15-30 mg/L when measured by HPLC, or 30-40 mg/L when measured by FPIA method. 
• Za endokarditis in druge hude okužbe: najnižja koncentracija teikoplanina 15-30 mg/l izmerjena s
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given Targocid. 
Če kaj od naštetega velja za vas (ali če ste negotovi), se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden dobite zdravilo Targocid.
As with other glycopeptides, ototoxicity (deafness and tinnitus) has been reported in patients treated with teicoplanin (see section 4.8). 
Tako kot med uporabo drugih glikopeptidov je tudi pri bolnikih, zdravljenih s teikoplaninom, opisana ototoksičnost (naglušnost in tinitus) (glejte poglavje 4.8).
• For people with severe kidney problems or on haemodialysis - the maintenance dose will be given every three days, or one-third of the maintenance dose will be given once a day. 
• Osebe s hudimi težavami z ledvicami in osebe na hemodializi dobijo vzdrževalni odmerek vsak tretji dan ali tretjino vzdrževalnega odmerka enkrat na dan.
They may also cause hearing problems and/or kidney problems. 
Lahko tudi povzročijo težave s sluhom, težave z ledvicami ali oboje.
• Week two: 20 mg/L in every other dialysis bag 
• drugi teden: 20 mg/l v vsako drugo dializno vrečko,
1 powder vial 
1 viala s praškom
Pharmacokinetic/Pharmacodynamic relationship 
Razmerje farmakokinetika/farmakodinamika
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions. 
Če ni uporabljeno takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika; čas običajno ne sme presegati 24 ur pri temperaturi od 2 do 8 °C, razen če ni priprava opravljena v nadzorovanih in preverjenih aseptičnih pogojih.
The reconstituted solution may be injected directly or alternatively further diluted, or orally administered. 
Pripravljeno raztopino se lahko injicira neposredno, lahko pa se jo dodatno razredči, ali se jo uporabi peroralno.
Uncommon (may affect up to 1 in 100 people) 
Občasni (pojavijo se lahko pri največ 1 od 100 oseb)
If you have kidney problems, your dose will usually need to be lowered after the fourth day of treatment: 
Odrasli in starejši bolniki, ki imajo težave z ledvicami Če imate težave z ledvicami, je treba odmerek po četrtem dnevu zdravljenja praviloma znižati:
• swelling and clotting in a vein 
• oteklost in strdek v veni
• For people with mild and moderate kidney problems - the maintenance dose will be given every two days, or half of the maintenance dose will be given once a day. 
• Osebe z blagimi ali zmernimi težavami z ledvicami dobijo vzdrževalni odmerek vsak drugi dan ali pol vzdrževalnega odmerka enkrat na dan.
One single dose of 10 mg/kg body weight administered intravenously every 12 hours, repeated 3 times. 
En odmerek 10 mg/kg telesne mase intravensko na 12 ur; to je treba ponoviti 3-krat.
Renal failure has been reported in patients treated with teicoplanin (see section 4.8). 
Pri bolnikih, zdravljenih s teikoplaninom, so poročali o odpovedi ledvic (glejte poglavje 4.8).
Streptococci in the viridans group a b Anaerobic Gram-positive bacteria Clostridium difficile a 
Anaerobne grampozitivne bakterije Clostridium difficile a
After a loading dose of 6 mg/kg administered intravenously every 12 hours for 3 to 5 administrations, Cmax values range from 60 to 70 mg/L and Ctrough are usually above 10 mg/L. 
Po polnilnem odmerku 6 mg/kg intravensko na 12 ur za 3 do 5 aplikacij je Cmax od 60 do 70 mg/l in Cnajnižja po navadi nad 10 mg/l.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions. 
Če ni uporabljeno takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika; čas običajno ne sme presegati 24 ur pri temperaturi od 2 do 8 °C, razen če ni priprava/redčenje opravljeno v nadzorovanih in preverjenih aseptičnih pogojih.
• Week three: 20 mg/L in the overnight dialysis bag. 
• tretji teden: 20 mg/l v dializno vrečko za čez noč.
For instructions on reconstitution and dilution of the medicinal product before administration, see section 
Za navodila o pripravi in razredčenju zdravila pred uporabo glejte poglavje 6.6.
Serious, life-threatening hypersensitivity reactions, sometimes fatal, have been reported with teicoplanin (e.g. anaphylactic shock). 
S teikoplaninom so bile opisane resne, življenje ogrožujoče preobčutljivostne reakcije, včasih s smrtnim izidom (npr. anafilaktični šok).
Other side effects Talk to your doctor, pharmacist or nurse if you get any of these: 
Drugi neželeni učinki Posvetujte se z zdravnikom, farmacevtom ali medicinsko sestro, če se vam pojavi kaj od naslednjega:
• water tablets (such as furosemide) - also called ‘diuretics' which may cause hearing problems and/or kidney problems. 
• tablete za odvajanje vode (na primer furosemid) - takšna zdravila imenujemo tudi "diuretiki";
Clostridium difficile infection-associated diarrhea and colitis The recommended dose is 100-200 mg administered orally twice a day for 7 to 14 days. 
Driska in kolitis, povezana z okužbo s Clostridium difficile Priporočeni odmerek je od 100 do 200 mg peroralno dvakrat na dan v trajanju od 7 do 14 dni.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte s svojim zdravnikom, s farmacevtom ali z medicinsko sestro.
The reconstituted solution may also be given by mouth. 
Pripravljeno raztopino je mogoče dati tudi peroralno.
• bone and joint infections, 
• okužbe kosti in sklepov,
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL OF POWDER VIAL 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH NALEPKA VIALE S PRAŠKOM
Only the infusion should be given in babies from birth to the age of 2 months. 
Dojenčki od rojstva do starosti 2 mesecev smejo zdravilo dobiti le v infuziji.
EXP Read the leaflet for the shelf life of the reconstituted medicine. 
EXP Za rok uporabnosti pripravljenega zdravila glejte navodilo za uporabo.
The starting dose is 6 mg for every kilogram of body weight, as a single injection into a vein, followed by: 
Peritonitis pri bolnikih na peritonealni dializi Začetni odmerek je 6 mg na kilogram telesne mase v enkratni injekciji v veno; temu sledi:
• Maintenance dose: 6 to 10 mg for every kilogram of body weight, given once a day, by injection into a vein. 
• Vzdrževalni odmerek: od 6 do 10 mg na kilogram telesne mase enkrat na dan z injekcijo v veno.
Volume withdrawable from the solvent ampoule for reconstitution 
Količina, ki jo je mogoče izvleči iz ampule z vehiklom za pripravo
• cisplatin - a medicine that treats malignant tumors which may cause hearing problems and/or kidney problems 
• cisplatin - zdravilo za zdravljenje malignih tumorjev, ki lahko povzroči težave s sluhom, težave z ledvicami ali oboje.
When administered by oral route teicoplanin is not absorbed from the gastrointestinal tract. 
Peroralno uporabljeni teikoplanin se ne absorbira iz prebavil.
Powder for solution for injection/infusion or oral solution: spongy ivory coloured homogeneous mass Solvent: clear, colourless liquid. 
Prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino: gobasta, homogena masa slonokoščene barve.
• you are taking other medicines which may cause hearing problems and/or kidney problems. 
• če jemljete druga zdravila, ki lahko povzročijo težave s sluhom, težave z ledvicami ali oboje.
After a maintenance dose of 6 mg/kg administered once daily Cmax and Ctrough values are approximately 70 mg/L and 15 mg/L, respectively. 
Po vzdrževalnem odmerku 6 mg/kg enkrat na dan je Cmax približno 70 mg/l in Cnajnižja približno 15 mg/l.
• The active substance is teicoplanin. 
• Zdravilna učinkovina je teikoplanin.
Where appropriate, teicoplanin should be administered in combination with other antibacterial agents. 
Teikoplanin je treba uporabiti v kombinaciji z drugimi protibakterijskimi zdravili, kadar je to primerno.
• ciclosporin - a medicine that affects the immune system which may cause hearing problems and/or kidney problems 
• ciklosporin - zdravilo, ki vpliva na imunski sistem; povzroči lahko težave s sluhom, težave z ledvicami ali oboje.
Tell your doctor or nurse straight away, if you notice any of the following serious side effects - you may need urgent medical treatment: 
Če opazite katerega od naslednjih resnih neželenih učinkov, takoj obvestite zdravnika ali medicinsko sestro - morda boste potrebovali nujno zdravniško pomoč:
• Starting dose (on the first day): 16 mg for every kilogram of body weight, as an infusion through a drip into a vein. 
• Začetni odmerek (prvi dan): 16 mg na kilogram telesne mase kot kapalna infuzija v veno.
- Complicated skin and soft tissue infections 
- Zapletene okužb kože in mehkih tkiv - Pljučnica - Zapletene okužbe sečil
After reconstitution, the solution will contain 100 mg teicoplanin in 1.5 mL. 
Po pripravi bo raztopina vsebovala 100 mg teikoplanina v 1,5 ml.
Deafness, hearing loss (see section tinnitus, vestibular disorder 
Ušesne bolezni, vključno z motnjami labirinta naglušnost, izguba sluha (glejte poglavje 4.4), tinitus, vestibularne motnje
Rare (≥1/10,000 to 
Redki do < 1/1.000)
(e.g. progressive skin rash often with blisters or mucosal lesions) are present teicoplanin treatment should be discontinued immediately. 
Če se pojavijo simptomi ali znaki SJS ali TEN (npr. napredujoč kožni izpuščaj, pogosto z mehurji ali spremembami na sluznici), je treba zdravljenje s teikoplaninom nemudoma končati.
• amphotericin B - a medicine that treats fungal infections which may cause hearing problems and/or kidney problems 
• amfotericin B - zdravilo za zdravljenje glivičnih okužb, ki lahko povzroči težave s sluhom, težave z ledvicami ali oboje.
For intramuscular, intravenous or oral uses 
za intramuskularno, intravensko ali peroralno uporabo
• Pain 
• bolečine
• peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD), • bacteraemia that occurs in association with any of the indications listed above. 
• peritonitis, povezan s kontinuirano ambulantno peritonealno dializo CAPD,
What Targocid looks like and contents of the pack Targocid is a powder for solution for injection/infusion or oral solution. 
Izgled zdravila Targocid in vsebina pakiranja Zdravilo Targocid je prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino.
PHARMACEUTICAL FORM AND CONTENTS Powder for solution for injection/infusion or oral solution 1 powder vial 
FARMACEVTSKA OBLIKA IN VSEBINA Prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino 1 viala s praškom
For Targocid, powder for solution for injection/infusion or oral solution What Targocid contains 
Za zdravilo Targocid prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Kaj vsebuje zdravilo Targocid
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL OF SOLVENT VIAL 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH NALEPKA VIALE Z VEHIKLOM
- Bone and joint infections 
- Okužbe kosti in sklepov
Tell your doctor if you are breast-feeding, before being given this medicine. 
Če dojite, morate to povedati zdravniku, preden dobite to zdravilo.
Teicoplanin should be administered by the intravenous or intramuscular route. 
Teikoplanin je treba uporabljati intravensko ali intramuskularno.
• Starting dose (for the first three to five doses): 800 mg (this equates to 12 mg for every kilogram of body weight), given every 12 hours, by injection into a vein or muscle 
• Začetni odmerek (za prve tri do pet odmerkov): 800 mg (to je enakovredno 12 mg na kilogram telesne mase) na 12 ur z injekcijo v veno ali mišico.
• Week one: 20 mg/L in each dialysis bag 
• prvi teden: 20 mg/l v vsako dializno vrečko,
12 mg/kg body weight intravenous or intramuscular once a day 
12 mg na kg telesne mase intravensko ali intramuskularno enkrat na dan
• epileptic fits Tell your doctor or nurse straight away, if you notice any of the side effects above. 
• epileptični napadi Če opazite katerega od omenjenih neželenih učinkov, takoj obvestite zdravnika ali medicinsko sestro.
After an intravenous loading dose of 12 mg/kg administered every 12 hours for 3 administrations, mean values of Cmax and Ctrough are estimated to be around 100 mg/L and 20 mg/L, respectively. 
Po polnilnem odmerku 12 mg/kg intravensko na 12 ur za 3 aplikacije je ocenjena povprečna Cmax okrog 100 mg/l, ocenjena povprečna Cnajnižja pa 20 mg/l.
1 powder vial with 1 solvent ampoule 5x1 powder vials with 5x1 solvent ampoules 10x1 powder vials with 10x1 solvent ampoules 25x1 powder vials with 25x1 solvent ampoules. 
1 viala s praškom z 1 ampulo z vehiklom 5 x 1 viala s praškom s 5 x 1 ampulo z vehiklom 10 x 1 viala s praškom s 10 x 1 ampulo z vehiklom 25 x 1 viala s praškom s 25 x 1 ampulo z vehiklom Na trgu morda ni vseh navedenih pakiranj.
• For most Gram-positive infections, teicoplanin trough levels of at least 10 mg/L when measured by 
• Za večino grampozitivnih okužb so izmerili najnižjo koncentracijo teikoplanina vsaj 10 mg/l s tekočinsko kromatografijo visoke ločljivosti (HPLC - High Performance Liquid Chromatography)
6 mg/kg body weight intravenous or intramuscular once a day 
6 mg na kg telesne mase intravensko ali intramuskularno enkrat na dan
• 10% dextrose injection 
• 10 % glukoza za injekcije
Nominal teicoplanin content of vial 
Nominalna količina teikoplanina v viali
5% dextrose injection 
5 % glukoza za injekcije
10x1 powder vials 25x1 powder vials Not all pack sizes may be marketed. 
5 x 1 viala s praškom 10 x 1 viala s praškom 25 x 1 viala s praškom Na trgu morda ni vseh navedenih pakiranj.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally] 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM [Glejte Prilogo I - Izpolni država članica]
5 powder vials 
5 vial s praškom
Each vial contains 400 mg teicoplanin equivalent to not less than 400,000 IU. 
Ena viala vsebuje 400 mg teikoplanina; to ustreza najmanj 400.000 i.e.
• Maintenance dose: 400 mg (this equates to 6 mg for every kilogram of body weight), given once a day, by injection into a vein or muscle 
• Vzdrževalni odmerek: 400 mg (to je enakovredno 6 mg na kilogram telesne mase) enkrat na dan z injekcijo v veno ali mišico.
• Maintenance dose: 8 mg for every kilogram of body weight, given once a day, as an infusion through a drip into a vein. 
• Vzdrževalni odmerek: 8 mg na kilogram telesne mase enkrat na dan kot kapalna infuzija v veno.
• you have kidney problems 
• če imate težave z ledvicami,
Infusion related reactions 
Z infundiranjem povezane reakcije
Each vial contains 200 mg teicoplanin equivalent to not less than 200,000 IU. 
Ena viala vsebuje 200 mg teikoplanina; to ustreza najmanj 200.000 i.e.
For Targocid, powder and solvent for solution for injection/infusion or oral solution - 1 powder vial with 1 solvent ampoule - 5x1 powder vials with 5x1 solvent ampoules - 10x1 powder vials with 10x1 solvent ampoules - 25x1 powder vials with 25x1 solvent ampoules 
Za zdravilo Targocid prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino - 1 viala s praškom z 1 ampulo z vehiklom - 5 x 1 viala s praškom s 5 x 1 ampulo z vehiklom - 10 x 1 viala s praškom z 10 x 1 ampulo z vehiklom - 25 x 1 viala s praškom s 25 x 1 ampulo z vehiklom
Each vial contains 100 mg teicoplanin equivalent to not less than 100,000 IU. 
Ena viala vsebuje 100 mg teikoplanina; to ustreza najmanj 100.000 i.e.
The primary literature, standard volumes and treatment recommendations assume sensitivity b Collective term for a heterogeneous group of streptococcus species. 
b Skupen izraz za heterogeno skupino vrst streptokokov.
You may have headaches or feel dizzy while being treated with Targocid. 
Med zdravljenjem z zdravilom Targocid se lahko pojavijo glavoboli ali omotica.
• feeling or being sick (vomiting), diarrhoea 
• občutek slabosti v želodcu (siljenje na bruhanje) ali bruhanje, driska
• complicated urinary tract infections, 
• zapletene okužbe sečil,
teicoplanin Intramuscular, intravenous or oral uses 
teikoplanin intramuskularna, intravenska ali peroralna uporaba
Volume of powder vial 
Količina v viali s praškom
One single dose of 8 mg/kg body weight administered intravenously by infusion once a day. 
Enkraten odmerek 8 mg/kg telesne mase v intravenski infuziji enkrat na dan.
• 5% dextrose injection 
• 5 % glukoza za injekcije
Thrombocytopenia has been reported with teicoplanin. 
Med uporabo teikoplanina so poročali o trombocitopeniji.
Targocid and associated names (see Annex I) 100 mg powder and solvent for solution for injection/infusion or oral solution Targocid and associated names (see Annex I) 200 mg powder and solvent for solution for injection/infusion or oral solution Targocid and associated names (see Annex I) 400 mg powder and solvent for solution for injection/infusion or oral solution 
Targocid in povezana imena (glejte Prilogo I) 100 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Targocid in povezana imena (glejte Prilogo I) 200 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Targocid in povezana imena (glejte Prilogo I) 400 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR 100 mg, 200 mg and 400 mg / powder and solvent for solution for injection/infusion or oral solution 
ZUNANJA OVOJNINA ZA 100 mg, 200 mg in 400 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Powder and solvent for solution for injection/infusion or oral solution Powder for solution for injection/infusion or oral solution 
Prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Loading dose regimen 
Shema polnilnih odmerkov
Special precautions must be taken when administering teicoplanin in patients who require concomitant treatment with ototoxic and/or nephrotoxic medicinal products for which it is recommended that regular haematology, liver and kidney function tests are carried out. 
Posebna previdno je treba teikoplanin uporabljati pri bolnikih, ki potrebujejo sočasno zdravljenje z ototoksičnimi in/ali nefrotoksičnimi zdravili.
For Targocid, powder for solution for injection/infusion or oral solution - 1 powder vial - 5x1 powder vials - 10x1 powder vials - 25x1 powder vials 
Za zdravilo Targocid prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino - 1 viala s praškom - 5 x 1 viala s praškom - 10 x 1 viala s praškom - 25 x 1 viala s praškom
• Maintenance dose: 800 mg (this equates to 12 mg for every kilogram of body weight), given once a day hours, by injection into a vein or muscle 
• Vzdrževalni odmerek: 800 mg (to je enakovredno 12 mg na kilogram telesne mase) enkrat na dan z injekcijo v veno ali mišico.
One single dose of 6-10 mg/kg body weight administered intravenously once a day. 
En odmerek 6-10 mg/kg telesne mase intravensko enkrat na dan.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR 100 mg, 200 mg and 400 mg / powder for solution for injection/infusion or oral solution 
ZUNANJA OVOJNINA ZA 100 mg, 200 mg in 400 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Preparation of reconstituted solution: Slowly inject the entire content of the supplied solvent into the powder vial. 
Počasi injicirajte celotno količino priloženega vehikla v vialo s praškom.
Targocid and associated names (see Annex I) 100 mg powder for injection/infusion or oral solution Targocid and associated names (see Annex I) 200 mg powder for injection/infusion or oral solution Targocid and associated names (see Annex I) 400 mg powder for injection/infusion or oral solution [See Annex I - To be completed nationally] 
Targocid in povezana imena (glejte Prilogo I) 100 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Targocid in povezana imena (glejte Prilogo I) 200 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Targocid in povezana imena (glejte Prilogo I) 400 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino [Glejte Prilogo I - Izpolni država članica]
After reconstitution, the solution will contain 200 mg teicoplanin in 3 mL. 
Po pripravi bo raztopina vsebovala 200 mg teikoplanina v 3 ml.
• you have a decrease in platelet count (thrombocytopenia) 
• če imate zmanjšano število krvnih ploščic (trombocitopenija),
Respiratory, thoracic and mediastinal disorders 
Bolezni dihal, prsnega koša in mediastinalne ga prostora bronhospazem
Teicoplanin is not distributed in red cells. 
Teikoplanin se ne porazdeli v eritrocite.
Management 
Vodenje
Powder for solution for injection/infusion or oral solution Sodium chloride 
Prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino natrijev klorid natrijev hidroksid (za prilagoditev pH)
One single dose of 16 mg/kg body weight, administered intravenously by infusion on the first day. 
Enkraten odmerek 16 mg/kg telesne mase v intravenski infuziji prvi dan. Vzdrževalni odmerek
After reconstitution, the solution will contain 400 mg teicoplanin in 3 mL. 
Po pripravi bo raztopina vsebovala 400 mg teikoplanina v 3 ml.
INSTRUCTIONS ON USE [To be completed nationally] 
NAČIN IZDAJANJA ZDRAVILA [Izpolni država članica]
After reconstitution, the solutions will contain 400 mg teicoplanin in 3.0 mL. 
Po pripravi bo raztopina vsebovala 400 mg teikoplanina v 3,0 ml.